drugset / Trial / NCT00051142

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142

Phase 3 Completed Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Timeline

Start
2001-02
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %
Subject Travoprost Other / unclassified 0.004 %